CTLA4 and metastatic melanoma: Since the CTLA4 inhibitor ipilimumab (the first ICB approved by the FDA) has significantly prolonged the OS of patients with metastatic melanoma, CTLA4 inhibitors have proven to be effective agents for many cancers [14].